Medical Efficacy of Cannabinoids and Marijuana: A Comprehensive Review of the Literature

O'Shaughnessy WB . On the preparation of Indian hemp or gunjah. Trans Med Physio Soc Bombay 1842; 8: 421–461.

Osier W , McRae T. The Principles and Practice of Medicine. Appleton, New York, 1915; p. 1225.

Berard CM , Mollereau G , Vassart H , Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279; 129–134.

Munro S , Thomas KL , Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61–65.

Galiegue S , Mary S , Marchand J , Dussossoy D , Carriere D , Carayon P , . Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54–61.

Devane WA , Hanus L , Breuer A , Pertwee RG , Stevenson LA , Griffin G , . Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946–1949.

Mechoulam R , Ben-Shabat S , Hanus L , Ligumsky M , Kaminski NE , Schatz AR , . Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharm 1995; 50: 83–90.

Hirst RA , Lambert DG , Notcutt WG . Pharmacology and potential therapeutic uses of cannabis. Br J Anaesth 1998; 81: 77–84.

Ameri A. The effects of cannabinoids on the brain. Prog Neuro 1999; 58: 315–348.

Piomelli D , Giuffrida A , Calignano A , Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21: 218–224.

Joy JE , Watson SJ , Benson JA (eds). U.S. Institute of Medicine (IOM). Marijuana and Medicine: Assessing the Science Base. National Academy Press, Washington, DC, 1999. Available at: www2.nas.edu.

Di Marzo V , Melck D , Bisogno T , De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 1998; 22 (2):80.

Carey MP , Burish TG , Brenner DE . Delta-9-tetracannabinol in cancer chemotherapy: research problems and issues. Ann Intern Med 1983; 99: 106–114.

Voth EA , Schwatrz RH . Medicinal applications of delta-9-tet-rahydrocannabinol and marijuana. Ann Intern Med 1997; 126: 791–798.

Dansak DA . Medical use of recreational drugs by AIDS patients. J Addict Dis 1997; 16 (3):25–30.

Mattes RD , Engelman K , Shaw LM , Elsohly MA . Cannabinoids and appetite stimulations. Pharm Bioch Behav 1994; 49:187–195.

Abrams DI , Leiser RJ , Shade SB , Hilton J , Elbeik T (THC Study Group). Short-term effects of cannabinoids on HIV-1 viral load [abstract]. Proc World AIDS Congress, 2000.

Mikuriya TH . International Classification of Diseases 9 CM 1996: Conditions Treated with Cannabis Encountered Between 1994–1998. 1998. Available at: www.drugsense.org/CCUA/ICD9.html.

Health Canada. Research Plan for Marijuana for Medicinal Purposes: a Status Report. Therapeutics Products Programme. 1999. Available at: <http://www.hc-sc.gc.ca>

Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialities. 1999; 34: 330, 999.

Block Rl , Wittenborn JR . Marijuana effects on the speed of memory retrieval in the letter-matching task. Int J Addict 1986; 21: 281–285.

Schwartz RH , Gruenewald PJ , Klitzner M , Fedio P. Short-term memory impairment in cannabis-dependent adolescents. Am J Dis Child 1989; 143: 1214–1219.

Pope HG , Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 1996; 275: 521.

Soderstrom CA , Trifillis AL , Shankar BS , Clark WE , Cowley RA . Marijuana and alcohol use among 1023 trauma patients. Arch Surg 1988; 123: 733–737.

Moskowitz H. Marijuana and driving. Accid Anal Prev 1985; 17: 323–345.

Wu TC , Tashkin DP , Djahed B , Rose JE . Pulmonary hazards of smoking marijuana smoke. N Engl J Med 1988; 318: 347–351.

Hoffman D , Brunneman DK , Gori GB , Wyder EL . On the carcinogenicity of marijuana smoke. Recent Adv Phytochem 1975; 126: 63–81.

Ungerleider JT , Andrysiak T , Tashkin DP , Gale DP . Contamination of marihuana cigarettes with pathogenic bacteria—possible sources of infection in cancer patients. Can Treat Rev 1982; 66: 589–591.

Hembree WC , Nahas GG , Zeidenberg P , Dyrenfurth I. Marihuana effects in human testis. Clin Res 1976; 24: 272A.

Cohen S. Marijuana on reproductive function. Drug Abuse & Alcoholism News 1985; 13: 1.

Fried PA , Watkinson B , Willan A. Marijuana use during pregnancy and decreased length of gestation. Am J Obstet Gynecol 1984; 150: 23–27.

Robison LL , Buckley JD , Daigle AE , Wells R , Benjamin D , Arthur DC , Hammond GD . Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. Cancer 1989; 63: 1904–1911.

Solomons K , Neppe VM , Kuyl JM . Toxic cannabis psychosis is a valid entity. S Afr Med J 1990; 78: 476–481.

Jones RT , Benowitz NL , Herning RI . Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981; 21: 143S–152S

Pertwee RG . Tolerance to and dependence on psychotropic cannabinoids. In: Pratt JA (ed). The Biological Basis of Drug Tolerance and Dependence. New York: Academic Press, 1991; pp. 231–263.

Haney M , Ward AS , Comer SD , Foltin RW , Fischman MW . Abstinence symptoms following oral THC administration to humans. Psychopharmacology 1999; 141: 385–394.

Haney M , Ward AS , Comer SD , Foltin RW , Fischman MW . Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 1999; 141: 395–404.

Goddard IW . Proven: Cannabis is Safe Medicine. 1996. Available at: www.erols.com/igoddard.

Health Canada. Regulation of Marihuana for Medical Purposes. 1998. Available at: www.hc-sc.gc.ca.

Health Canada. Interim Guidance Document: Therapeutic Products Programme, Exemption under Section 56 for Medical Purposes. 2000. Available at: www.hc-sc.gc.ca.

Hall W. The cannabis policy debate: finding a way forward. CMAJ 2000; 162: 1690–1692.

Penta JS , Poster DS , Bruno S , Macdonald JS . Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. J Clin Pharmacol 1981; 21: 11S–22S.

Poster DS , Penta JS , Bruno S , Macdonald JS . Delta-9-tetrahydrocanabinol in clinical oncology. JAMA 1981; 245: 2047–2051.

Sallan SE , Zinberg NE , Frei E. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293 (16):795–797.

Kluin-Neleman JC , Neleman FA , Meuwissen OJ , Maes RA . delta-9-tetrahydrocannabinol (THC) as an anti-emetic in patients treated with cancer chemotherapy: a double-blind, cross-over trial against placebo. Vet Hum Toxicol 1979; 21 (5):338–340.

Lucas VC , Laszlo J. Delta-9-tetrahydrocannabinol for refractory vomiting induced by chemotherapy. JAMA 1980; 243:1241–1243

Sweet DL , Miller NJ , Weddington W , Senay E , Sushelsky L. Delta-9-Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study. J Clin Pharmacol 1981; 21: 70S–75S.

Chang AE , Shiling DJ , Stillman RC , Goldberg NH , Seipp CA Barofsky I , Rosenberg SA . A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and Cytoxan chemotherapy. Cancer 1981; 47: 1746–1751.

Frytak S , Moertel CG , O'Fallon Jr , Rubin J , Creagan ET , O'Connell MJ , . Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 1979; 91 (6):825–830.

Ungerleider JT , Andrysiak T , Fairbanks L , Goodnight J , Sarna G , Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-tetrahydrocannabinol and prochlorperazine. Cancer 1982; 50: 636–645.

Sallan SE , Cronin C , Zelen M , Zinberg NE . Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980; 302 (3):135–138.

Orr LE , McKernan JF . Antiemetic effect of delta-9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol 1981; 21(8–9 suppl): 76S–80S.

Levitt M , Wilson A , Bowman D , Kernel S , Krepart G , Marks V . Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, 15 mg of delta-9-tetrahydrocannabiinol in cancer chemotherapy. J Clin Pharmacol 1981; 21: 103S–109S.

McCabe M , Smith FP , Macdonald JS , Woolley PV , Goldberg D , Schein PS . Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 1988; 6 (3):243–246.

Niiranen A , Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol 1985; 8 (4):336–340.

Herman TS , Einhorn LH , Jones SE , Nagy C , Chester AB , Dean JC . Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979; 300 (23):1295–1297.

Steele N , Gralla RJ , Braun DW , Young CW . Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep 1980; 64: 219–224.

Einhorn LHH , Nagy C , Furnas B , Williams SD . Nabilone: a effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 1981; 21: 64S–69S.

Ahmedzai S , Carlyle DL , Calder It , Moran F. Antiemetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 1983; 48 (5):657–663.

Garb S , Beers AL , Bograd M , McMahon RT , Mangalik A , Ashmann AC , Levine S. Two-pronged study of tetrahydrocannabinol (THC) prevention of vomiting from cancer chemotherapy. IRCS Med Sci 1980; 8: 203–204.

McCabe M , Smith FP , Goldberg D , Macdonald J , Wooley PV , Warren R , . Comparative trial of oral delta-9-tetrahydrocannabinol (THC) and prochlorperazine (PCZ) for cancer chemotherapy-related nausea and vomiting. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 1981; 22: 416.

Lane M , Vogel CL , Ferguson J , Krasnow S , Saiers JL , Hamm J , . Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting J Pain Symptom Manage 1991; 6: 352–359.

Cunningham D , Forrest GJ , Soukop M , Gilchrist NL , Calder IT , McArdle CS . Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs. Br Med J 1985; 291: 864–865.

Gonzales-Rosales F , Walsh D. Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (dronabinol). J Pain Symptom Manage 1997; 14: 311–314.

Ekert H , Waters KD , Jurk IH , Mobilia J , Loughnan P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust 1979; 2: 657–659.

Dalzell AM , Bartlett H , Lilleyman JS . Nabilone: an alternative antiemetic for cancer chemotherapy. Arch Dis Child 1986; 61 (5):502–505.

Chan HS , Correia JA , MacLeod SM . Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987; 79 (6):946–952.

Colls BM , Ferry DG , Gray AJ , Harvey VJ , McQueen EG . The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. NZ Med J 1980; 91: 449–451.

Meyer Br , Lewin M , Drayer DE , Pasmantier M , Lonski L , Reidenberg MM . Optimizing metoclopramide control of cisplatin induced emesis. Ann Int Med 1984; 100: 393–395.

Kerr DJ , Graham J , Blackie RG , McGovern E , Kelman AW , Cunningham D , Kaye SB . The relationship between steady state metoclopramide levels and control of emesis during treatment with cis-platinum. Br J Clin Pharmacol 1985; 20: 426–427.

Allan SG , Cornbleet MA , Warrington PS , Golland IM , Leonard RC , Smyth JN . Dexamethasone and high-dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. Br Med J 1984; 289: 878–879.

Gralla RJ , Tyson LB , Clark RA , Bordin LA , Kelsen DP , Kalman LB . Antiemetic trials with high dose metoclopramide: superiority over THC, and preservation of efficacy in subsequent chemotherapy courses [abstract]. Proc Am Soc Clin Oncol 1982; 1: 58.

Cunningham D , Bradley CJ , Forrest GJ , Hutcheon AW , Adams L , Sneddon M , . A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 1988; 24: 685–689.

Vinciguerra V , Moore T , Brennan E. Inhalation marijuana as an antiemetic for cancer chemotherapy. N Y State J Med 1988; 88: 525–527.

Chang AE , Shiling DJ , Stillman RC , Goldberg NH , Seipp CA , Barofsky I , . Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 1979; 91 (6):819–824.

Levitt M , Faiman C , Hawks R , Wilson A. Randomized double blind comparison of delta-9-tetrahydrocannabinol and marijuana as chemotherapy antiemetics [abstract]. Proc Am Soc Clin Oncol 1984; 3: 91.

Neidhart JA , Gagen MM , Wilson HE , Young DC . Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol 1981; 21: 38S–42S.

Pomeroy M , Fennelly JJ , Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 1986; 17 (3):285–288.

Lucraft HH , Palmer MK . Randomized clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clin Radiol 1982; 33 (6):621–622.

Staquet M , Bron D , Rozencweig M , Kenis Y. Clinical studies with a THC analog (BRL-4664) in the prevention of cisplatin-induced vomiting. J Clin Pharmacol 1981; 21: 60S–63S.

Diasio RB , Ettinger DS , Satterwhite BE . Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations. J Clin Pharmacol 1981; 21: 81S–85S.

Laszlo J , Lucas VS , Hanson DC , Cronin CM , Sallan SE . Levonantradol for chemotherapy-induced emesis: phase l-ll oral administration. J Clin Pharmacol 1981; 21: 51S–56S.

Heim ME , Romer W , Queisser W. Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nauseas and vomiting. J Clin Pharmacol 1981; 21: 86S–89S.

Stambaugh JE , McAdams J , Vreeland F. Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. J Clin Pharmacol 1984; 24(11–12): 480–485.

Cronin CM , Sallan SE , Gelber R , Lucas VS , Laszlo J. Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. J Clin Pharmacol 1981; 21: 43S–50S.

Sheilder VR , Ettinger DS , Diasio RB , Enterline JP , Brown MD . Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. J Clin Pharmacol 1984; 24 (4):155–159.

Hutcheon AW , Palmer JB , Soukop M , Cunningham D , McArdle C , Welsh J , . A randomized multicentre single blind comparison of a cannabinoid antiemetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. Eur J Cancer Clin Oncol 1983; 19 (8):1087–1090.

Citron ML , Herman TS , Vreeland F , Krasnow SH , Fossieck BE , Harwood S , . Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 1985: 69(1): 109–112.

Flynn J , Hanif N. Nabilone for the management of intractable nausea and vomiting in terminally staged AIDS. J Palliat Care 1992; 8: 46–47.

Green ST , Nathwani D , Goldberg D , Kennedy DH . Nabilone as effective therapy for intractable nausea and vomiting in AIDS. Br J Clin Pharmacol 1989; 28: 494–495.

Buxbaum DM . Analgesic activity of delta-9-tetrahydrocannabinol in the rat and mouse. Psychopharmacol 1972: 275–280.

Martin BR . Characterization of the antinociceptive activity of intravenously administered delta-9-tetrahydrocannabinol in mice. In: Harvey DJ (ed). Marihuana ‘84. Oxford: IRL Press, 1985; pp. 685–691.

Compton DR , Aceto MD , Lowe J , Martin BR . In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta-9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996; 277: 586–594.

Martin WJ , Coffin PO , Attias E , Balinsky M , Tsou K , Walker JM . Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 1999; 822: 237–242.

Lichtman AH , Martin BR . Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 1991; 258: 517–523.

Lichtman AH , Martin BR . Cannabinoid-induced antinociception is mediated by spinal alpha-2-noradrenergic mechanism. Brain Res 1991; 559: 309–314.

Smith PB , Martin BR . Spinal mechanisms of delta-9-tetrahydrocanabaniol-induced analgesia. Brain Res 1992; 578: 8–12.

Richardson JD , Kilo S , Hargreaves KM . Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998; 75: 111–119.

Lichtman AH , Cook SA , Martin BR . Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaquaductal gray involvement. J Pharmacol Exp Ther 1996; 276: 585–593.

Welch SP , Stevens DL . Antinociceptive activity of intrathecally administered cannabinoids alone and in combination with morphine, in mice. J Pharmacol Exp Ther 1992; 262(1): 10–18

Reche I , Feutes JA , Ruiz-Gayo M. Potentiation of D-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of m- and k-opioid receptors. Eur J Pharmacol 1996; 318: 11–16.

Cichewicz DL , Martin ZL , Smith FL , Welch SP . Enhancement of mu opioid antinociception by oral delta-9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 1999; 289 (2):859–867.

Smith FL , Cichewicz D , Martin ZL , Welch SP . The enhancement of morphine antinociception in mice by delta-9-tetrahydrocannabinol. Pharmacol Biochem Behav 1998; 60 (2):559–566.

Ledent C , Valverde O , Cossu G , Petitet F , Aubert JF , Beslot F , . Unresponsiveness to cannabinoids and reduced additive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401–404.

Vela G , Ruiz-Gayo M , Feuntes JA . Anandamide decreases naxolone precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 1995; 34: 665–668.

Martin BR , Lichtman AH . Cannabinoid transmission and pain perception. Neurobiol Dis 1998; 5: 447–461.

Calignano A , La Rana G , Giuffrida A , Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394 (6690):277–281.

Noyes R Jr , Brunk SF , Baram DA , Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975; 15: 139–143.

Noyes R Jr , Brunk SF , Baram DA , Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharm Ther 1975; 18: 84–89.

Jochimsen PR , Lawton RL , VerSteeg K , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC cogener, on pain. Clin Pharmacol Ther 1978; 24: 223–227.

Staquet M , Gantt C , Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 1978; 23: 397–401.

Raft D , Gregg J , Ghia J , Harris L. Effects of intravenous tetrahydrocannabinol on experimental surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther 1977; 21: 26–33.

Hill SY , Schwin R , Goodwin DW , Powell BJ . Marihuana and pain. J Pharmacol Exp Ther 1974; 188: 415–418.

Milstein SL , MacCannell K , Karr G , Clark S. Marijuana-produced changes in pain tolerance. Experienced and non-experienced subjects. Int Pharmacopsychiatry 1975; 10: 177–182.

Hamann W , di Vadi PP . Analgesic effect of the cannabinoid analog nabilone is not mediated by opioid receptors. Lancet 1999; 353: 560.

Holdcroft A , Smith M , Jacklin A , Hodgson H , Smith B , Newton M , Evans F. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997; 52: 483–486.

Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain 1998; 76: 3–8.

Volfe Z , Dvilansky A , Nathan I. Cannabinoids block release of serotonin form platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res 1985; 5: 243–246.

El-Mallakh RS . Marijuana and migraine. Headache 1987; 27: 442–443.

El-Mallakh RF . Migraine headaches and drug abuse. South Med J 1989; 82: 805.

Beal JE , Olson R , Lefkowitz L , Laubenstein L , Bellman P , Yangco B , . Long-term efficacy of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14 (1):7–14.

Nelson KA , Walsh D , Deeter P , Sheehan F. A phase II trial of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994A; 10 (1):14–18.

Jakowiak NT , Alexander HR . The pathophysiology of cancer cachexia. In: Doyle D , Hanks G , MacDonald N (eds). Oxford Textbook of Palliative Medicine (2nd ed.) Oxford: Oxford University Press, 1999; pp. 534–548.

Hollister L. Hunger and appetite after single doses of marihuana, alcohol and dextroamphetamine. Clin Pharmacol Ther 1970; 12: 44–49.

Abel EL . Effects of marihuana on the solution of anagrams, memory and appetite. Nature 1971; 231: 2660–2661.

Gagnon MA , Elie R. Effects of marijuana and D-amphetamine in the appetite, food consumption and various cardio-respiratory variables in man. Union Med Can 1975; 104 (6):914–921.

Mattes RD , Engelman K , Shaw LM , Elsohly MA . Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 1994; 49 (1):187–195.

Regelson W , Butler Jr , Schulz J , Kirk T , Peek L , Green ML , Zalis MO . Delta-9-tetracannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Braude MC , Szara S (eds). The Pharmacology of Marijuana. New York: Raven Press, 1976; pp. 763–775.

Plasse TF , Gorter RW , Krasnow SH , Lane M , Shepard KV , Wadleigh RG . Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40: 695–700.

Gorter R , Seefried M , Volberding P. Dronabinol effects on weight in patients with HIV infection. AIDS 1992; 6: 127.

Timpone JG , Wright DJ , Li N , Egorin MJ , Enama ME , Mayers J , Galetto G. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retroviruses 1997; 1 (13):305–315.

Beal JE , Olson R , Laubenstein L , Morales JO , Bellman P , Yangco B , . Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10 (2):89–97.

Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 1998; 5: 534–551.

Consroe P , Musty R , Rein J , Tillery W , Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997: 38(1): 44–48.

Petro DJ , Ellenberger C. Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21(suppl 8–9): 413S–16S.

Ungerleider JT , Andyrsiak T , Fairbanks L , Ellison GW , Myers LW . Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7 (1):39–50.

Greenberg HS , Werness SA , Pugh JE , Andrus RO , Anderson DJ , Domino EF . Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994; 55 (3):324–328.

Kiplinger GF , Manno JE , Rodda BE , Forney RB . Dose-response analysis of the effects of tetrahydrocannabinol in man. Clin Pharmacol Ther 1971; 12: 650–657

Martyn CN , lllis LS , Thorn J. Nabilone in the treatment of multiple sclerosis. Lancet 1995; 345 (8949):597.

Meinck HM , Schonle PW , Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989; 236 (2):120–122.

Clifford DB . Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983; 13 (6):669–671.

Karler R , Turkanis SA . The cannabinoids as potential antiepileptics. J Clin Pharmacol 1981; 21: 437S–448S.

Cunha JM , Carlini EA , Pereira AE , Ramos OL , Pimentel C , Gagliardi R , Sanvito WL . Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21: 175–185.

Perez-Reyes M , Wingfield M. Cannabidiol and electroencephalographic epileptic activity [letter]. JAMA 1974; 230 (12):1635.

Keeler MH , Reifer CF . Grand mal convulsions subsequent to marijuana use. Dis Nerv Syst 1967; 28: 474–475.

Chiu P , Olsen DM , Borys HK , Karler R , Turkanis SA . The influence of cannabinoid and delta-9-tetrahydrocannabinol on cobalt epilepsy in rats. Epilepsia 1979; 20: 365–375.

Karler R , Turkanis SA . Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice. Br J Pharmacol 1980; 68: 479–484.

Consroe P , Martin A , Singh V. Antiepileptic potential of cannabidiol analogs. J Clin Pharmacol 1981; 21: 428S–436S.

Feeney DM . Marihuana and epilepsy: paradoxical anticonvulsant and convulsant effects. Adv Biosci 1978; 22–23: 643–657.

Feeney DM , Spiker MD , Weiss G. In: Cohen S , Stillman RC (eds). The Therapeutic Potential of Marijuana. New York: Plenum, 1976; p. 343.

Craigmill AL . Cannabinoids and handling-induced convulsions. Res Comm Psychol Psychiat Behav 1979; 4: 51–63.

Turkanis SA , Karler R. Electrophysiologic properties of the cannabinoids. J Clin Pharmacol 1981; 21: 449S–463S.

Consroe PF , Wood GC , Buchsbaum H. Anticonvulsant nature of marihuana smoking. JAMA 1975; 234 (3):306–307.

Ellison JM , Gelwan E , Ogletree J. Complex partial seizure symptoms affects by marijuana abuse. J Clin Psychiatry 1990; 51 (10):439–440.

Gilson I , Bussalacchi M. Marijuana for intractable hiccups. Lancet 1998; 351: 267.

Albrecht H , Steelbrink HJ . Hiccups in people with AIDS. J Acquir Immune Defic Syndr 1994; 7: 735.

Hanks G , Portenoy RK , MacDonald N , Forbes K. Difficult pain problems. In: Doyle D , Hanks G , MacDonald N (eds). Oxford Textbook of Palliative Medicine (2nd ed.) Oxford: Oxford University Press, 1999; p. 454.